Carboexpert Inc. has identified compounds acting as interleukin-1β (IL-1β), interleukin-8 (IL-8; CXCL8) and TNF-α production inhibitors reported to be useful for the treatment of allergy, sepsis and inflammation.
An Oncolinea Pharmaceuticals Inc. patent describes nucleosides acting as DNA repair inhibitors and thus reported to be useful for the treatment of cancer.
A team at the University of Geneva has developed prodrugs of antimicrobial agents and particularly conjugates comprising antimicrobial agents covalently bound to a tocopheryl or tocotrienyl group through a linker with micelle formation ability and improved stability.
Gliomas are the most common brain tumors. Adult gliomas frequently present molecular alterations in the epidermal growth factor receptor (EGFR) and its associated signaling pathways. In recent work, researchers from the Centre de Biophysique Moléculaire (France) and collaborators demonstrated the role of the serotonin 5-HT7 receptor (5-HT7R) in a larval Drosophila model of glioma, showing that it may act as a tumor suppressor.
Researchers from Boehringer Ingelheim Pharma GmbH & Co. KG presented the discovery and preclinical characterization of BI-3706674, a potent and orally available small-molecule inhibitor of the KRAS oncogene, targeting both KRAS-mutant and KRAS wild-type amplified (WTamp) cancers.
Can-Fite Biopharma Ltd. has entered into an agreement with Collaborations Pharmaceuticals Inc. (CPI) to develop anticancer drugs utilizing artificial intelligence (AI) and machine learning (ML) techniques.
Researchers from Università degli Studi di Foggia presented data from a study that aimed to investigate different circulating microRNAs (miRNAs) as possible biomarkers for the diagnosis and prognosis of multiple sclerosis (MS).
Heat shock protein 90 (Hsp90) consists of four isoforms. Among them, the Hsp90α is overexpressed in advanced tumors and involved in tissue repair, tumor migration and metastasis as well. Researchers from Fujian Medical University (FJMU) reported on the discovery and preclinical characterization of [I], a selective proteolysis targeting chimera (PROTAC) acting as an Hsp90α protein degradation inducer for breast cancer treatment.
Triveni Bio Inc. has announced a $92 million series A financing that will support the advancement of its lead antibody program, TRIV-509, from preclinical development to a phase IIa clinical trial in atopic dermatitis and fuel a pipeline of novel antibodies with two additional development candidate nominations expected in 2024.
RSS
